GRAIL, LLC

GRAIL, Inc. is a healthcare company focused on early cancer detection. Its primary product is the Galleri multi-cancer early detection (MCED) blood test, which uses next-generation sequencing and targeted methylation analysis to detect DNA shed by cancer cells and identify the tissue of origin. The Galleri test screens for multiple cancer types, including many without existing recommended screening methods such as pancreatic, esophageal, ovarian, and liver cancers. The test is currently available as a laboratory-developed test under CLIA and is recommended for adults aged 50 or older with elevated cancer risk. GRAIL has submitted a Premarket Approval (PMA) application to the FDA and anticipates an advisory committee review in fall 2026. The company's clinical evidence base includes results from the 140,000-participant NHS-Galleri randomized controlled trial and the 25,000-participant PATHFINDER 2 study. GRAIL also offers development services revenue and maintains a targeted methylation-based platform supporting precision oncology applications including minimal residual disease detection, biomarker subtyping, and recurrence monitoring. The company trades on Nasdaq under the ticker GRAL. Updated Aug 5, 2026